Jason R Brown

18PUBLICATIONS

99CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Central and Eastern European languages (incl. Russian)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (18)

Sort by Publication Date:

|May 21, 2026

Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinoma.

|Feb 27, 2026

Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.

Abby L Grier, Jeffrey Y Zhong, Spyridon Basourakos

|Feb 09, 2026

Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.

Abdul Rahman Al Armashi, Jenny Gong, Pedro Barata

|Dec 20, 2025

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Georges Gebrael, Neeraj Agarwal, Alicia K Morgans

|Dec 09, 2025

Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.

Jason R Brown, Guru Sonpavde

|Nov 06, 2025

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

Pageof 3

Frequent Collaborators

Albert Jang

Pedro C Barata

Laura Bukavina

Angela Y Jia

Henkel Valentine

Shilpa Gupta

Elizabeth R Plimack

Philip H Abbosh

Randy Vince

Adam Calaway

Frequent Collaborators

Albert Jang

Pedro C Barata

Laura Bukavina

Angela Y Jia